Xcout Intel
Maze Therapeutics, Inc. competitors & alternatives
The 12 closest competitors and alternatives to Maze Therapeutics, Inc. among drug discovery companies — ranked by similarity to what Maze Therapeutics, Inc. actually does, not by market-cap band.
Subscribe to see Maze Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Maze Therapeutics, Inc.
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
Maze Therapeutics, Inc. at a glance
Maze Therapeutics, Inc. is a drug discovery company headquartered in South San Francisco, United States. It is publicly listed (MAZE) with a market capitalisation of $1.5B. Xcout tracks 38 named people at Maze Therapeutics, Inc., including Jason V. Coloma (Chief Executive Officer & Director). Xcout recorded 29 job postings from Maze Therapeutics, Inc. in the last 90 days.
Maze Therapeutics, Inc. leadership
- Jason V. ColomaChief Executive Officer & Director
- Jason ColomaChief Executive Officer
- Harold S. BernsteinPresident of Research & Development and Chief Medical Officer
- Harold BernsteinPresident, Research and Development and Chief Medical Officer
- Misbah TahirCFO & Principal Accounting Officer
- Atul DandekarChief Strategy & Business Officer
32 more named people on record for Maze Therapeutics, Inc., with roles, board committees and tenure — see the full roster →
Hiring at Maze Therapeutics, Inc.
Xcout recorded 29 job postings from Maze Therapeutics, Inc. in the last 90 days, from a hiring record Xcout has kept since June 2026.
The weekly hiring trend, the roles and locations behind it — see Maze Therapeutics, Inc.'s hiring signals →
Top 12 Maze Therapeutics, Inc. competitors
Ranked by semantic similarity — how close each company is to Maze Therapeutics, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biopharma
Glycomine, Inc. is a biotherapeutics company focused on developing replacement therapies and treatments for serious rare genetic diseases, operating out of major life science hubs in San Francisco and Boston.
Similar drug discovery company
Ochre Bio is a biotechnology company developing precision medicines for chronic liver diseases. It uses data from human donor livers, computational biology, and experimental models to identify and validate therapeutic targets for pharmaceutical and biotechnology development.
Similar drug discovery company
Alebund Pharmaceuticals is a biopharmaceutical company founded in early 2018 in Shanghai, China, with operations also in Yangzhou City, focusing on the discovery and development of treatments for kidney disease.
Similar drug discovery company
Prazer Therapeutics is a biotechnology company founded in 2019 and headquartered in Seoul, South Korea. The company focuses on developing orally available, brain-penetrating small molecule therapeutics utilizing targeted protein degradation technology for novel drug discovery.
Similar drug discovery company
Renibus Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Southlake, Texas, dedicated to transforming outcomes in specialty therapeutics and disease treatments.
Similar drug discovery company
Metsera, Inc. is a clinical-stage biopharmaceutical company traded on the NASDAQ under the symbol MTSR, with its headquarters located in New York, New York, focusing on next-generation obesity and metabolic portfolios.
Similar drug discovery company
Nura Bio Inc. is a privately held biopharmaceutical company headquartered in South San Francisco, California, founded in 2018 to develop novel treatments for neurological diseases.
Medtech
IAMA Therapeutics is a clinical-stage pharmaceutical and biotechnology company founded in 2021 and headquartered in Genoa, Italy. The firm is dedicated to researching and developing innovative, disease-modifying medicines to treat brain disorders.
Biopharmaceuticals
Allena Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in Newton, Massachusetts, focused on the research, development, and commercialization of orally administered enzyme therapeutics for rare and severe metabolic and kidney disorders.
Biopharmaceuticals
Amicus Therapeutics, Inc. is an American biopharmaceutical company based in Princeton, New Jersey, dedicated to advancing therapies to treat rare diseases.
Biopharmaceuticals
BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying, advancing, and providing medical solutions for various genetic conditions. The firm boasts an extensive portfolio comprising 30 distinct development initiatives, spanning the entire spectrum from initial discovery research to advanced clinical trial phases. Notable candidates within its development pipeline include: AG10 and BBP-265: A small molecule designed to stabilize transthyretin (TTR), currently in a pivotal Phase 3 clinical trial targeting transthyretin amyloidosis-cardiomyopathy (ATTR-CM). BBP-831: A selective small molecule inhibitor of FGFR1-3, which is undergoing Phase 2 clinical evaluation for treating achondroplasia in pediatric patients. BBP-631: An AAV5 gene transfer product candidate, also in Phase 2 clinical trials, aimed at congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency (21OHD). Furthermore, BridgeBio is developing: Encaleret: A small molecule antagonist of the calcium sensing receptor (CaSR), presently in a Phase 2 proof-of-concept study for Autosomal Dominant Hypocalcemia Type 1 (ADH1). BBP-711: Intended for the management of hyperoxaluria and individuals prone to recurring kidney stones. Beyond these specific programs, the company is actively engaged in developing therapies for a broader range of Mendelian disorders, oncological diseases, and gene therapy applications. BridgeBio Pharma, Inc. maintains strategic licensing and collaboration agreements with institutions such as Leland Stanford Junior University, The Regents of the University of California, and Leidos Biomedical Research, Inc. Established in 2015, the company's corporate headquarters are situated in Palo Alto, California.
Biopharmaceuticals
Madrigal Pharmaceuticals, Inc. is a fully integrated biopharmaceutical company headquartered in West Conshohocken, Pennsylvania. The company focuses on delivering novel therapeutics for metabolic dysfunction-associated conditions.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Maze Therapeutics, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Maze Therapeutics, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →